An observational study in Obstructive Hypertrophic Cardiomyopathy, sponsored by Bristol-Myers Squibb. Recruiting at 101 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.
Sponsored by Bristol-Myers Squibb · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb — 10 open to participants now, 15 under way, 2 of them phase 3. Cardiomyopathy, Hypertrophic · Bristol-Myers Squibb.
Among the 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb, this one has the largest planned enrollment of the 15 observational ones that give a count, is one of 4 that started in 2022, is one of 15 observational ones, reaches primary completion later than 13 of the 14 other live ones, and was the 11th registered.
365 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 118 are open to participants now.
Browse Cardiomyopathy, Hypertrophic studies →10 of the 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Japan
Ages 18+
Bristol-Myers Squibb · Sites in China
Ages 18+
Bristol-Myers Squibb · Sites in United Kingdom
Ages 18+
Bristol-Myers Squibb · Sites in Japan
Ages 18+
Bristol-Myers Squibb · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Of the 82 Cardiomyopathy, Hypertrophic studies recruiting now, 56 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 7 · Phase 4 2
First in 2014; this study’s year is marked. 4 started in 2022.
This study's planned enrollment of 1,700 is above the median of 259 across 174 observational studies indexed under Cardiomyopathy, Hypertrophic.
Median enrollment 59 across the 17 interventional studies, 200 across the 15 observational. Of the 17 that completed or were terminated, 8 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
6 of the studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06146660Bristol-Myers SquibbA Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy | 2026-11-30 |
| NCT07557498Bristol-Myers SquibbMavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US | 2026-12-14 |
| NCT07541833Bristol-Myers SquibbEffectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM) | 2026-12-31 |
| NCT06551129Bristol-Myers SquibbReal-world Patient Reported Outcomes Among Patients Treated With Camzyos | 2026-12-31 |
| NCT07846059Bristol-Myers SquibbEvaluation of Mavacamten-Based Practice in Chinese Adults With Obstructive Hypertrophic Cardiomyopathy | 2027-03-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This registry evaluates patient characteristics, real-world treatment patterns, and short- and long-term outcomes in a population of patients in the United States and Europe with symptomatic obstructive hypertrophic cardiomyopathy (HCM) who are receiving mavacamten, receiving other treatment for obstructive HCM, or not receiving treatment for obstructive HCM due to intolerance or failure of prior treatment.
United States Sub-Study: The purpose of this study is to evaluate the safety of mavacamten in patients with symptomatic obstructive HCM in the real-world setting.
Europe Sub-Study: The purpose of this study is to evaluate the effectiveness and safety of mavacamten in patients with symptomatic obstructive HCM in the real-world setting.
The study population will include adult participants with symptomatic obstructive HCM who are receiving pharmacological treatment for obstructive HCM (for example, BBs, non-DHP CCBs, disopyramide, and/or mavacamten) as part of routine care in the United States or Europe.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
United States Sub-Study
Diagnosis of obstructive HCM consistent with 2020 American Heart Association/American College of Cardiology (AHA/ACC) guidelines.
European Sub-study
Exclusion Criteria
United States Sub-Study
European Sub-study
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive mavacamten as prescribed by a physician according to standard of care for symptomatic oHCM
Drug: Mavacamten
Participants will receive BB/non-DHP CCB/disopyramide as prescribed by a physician according to standard of care for symptomatic oHCM
Drug: Non-mavacamten symptomatic oHCM therapy
As per product label
Including Beta-blocker (BB), non-dihydropyridine (non-DHP) calcium channel blocker (CCB) and/or disopyramide as per product label
Incidence rate of new or worsening heart failure due to systolic dysfunction among participants with symptomatic obstructive HCM during periods of exposure to mavacamten and other oHCM treatment
Systolic dysfunction defined as symptomatic Left Ventricular Ejection Fraction (LVEF) \< 50%. United States participants only.
Time frame: Up to 5 Years
Change in resting left ventricular outflow tract (LVOT) gradient from baseline
European Participants only
Time frame: Up to 18 months
Occurrence of arrhythmia
Incidence rates of participants with arrhythmia (new onset)
Time frame: Baseline, and up to 18 months (European participants), or 5 Years (United States participants)
New or worsening heart failure due to systolic dysfunction
Symptomatic left ventricular ejection fraction (LVEF) \<50%. European Participants only
Time frame: Baseline and up to 18 months
Proportion of participants with a resting or provoked peak left ventricular outflow tract (LVOT) gradient below 50 mmHG
European participants only
Time frame: Baseline and up to 18 months
Proportion of participants with a resting or provoked peak left ventricular outflow tract (LVOT) gradient below 30 mmHG
European participants only
Time frame: Baseline and up to 18 months
Occurrence of Major Adverse Cardiovascular Events (MACE)
A composite endpoint consisting of non-fatal acute Myocardial Infarction (MI), stroke, hospitalization due to Heart Failure (HF) and Cardiovascular (CV) mortality. United States participants only.
Time frame: Up to 5 Years
Occurrence of non-fatal acute Myocardial Infarction (MI)
United States participants only
Time frame: Up to 5 Years
Occurrence of Stroke
United States participants only
Time frame: Up to 5 Years
Occurrence of hospitalization due to heart failure
Time frame: Baseline, and up to 18 months (European participants), or 5 Years (United States participants)
Occurrence of cardiovascular mortality
United States participants only
Time frame: Up to 5 Years
Occurrence of all-cause mortality
Time frame: Baseline, and up to 18 months (European participants), or 5 Years (United States participants)
Evaluation of functional responses: New York Heart Association (NYHA) function class
Percentage of Participants Whose NYHA Class Changes
Time frame: Baseline, and up to 18 months (European participants), or 5 Years (United States participants)
Evaluation of functional responses: Left Ventricular Outflow Tract (LVOT) gradient
Mean Change From Baseline in LVOT Gradients At Rest and Provoked
Time frame: Baseline, and up to 18 months (European participants), or 5 Years (United States participants)
Evaluation of functional responses: LVEF
Mean Change from Baseline in LVEF
Time frame: Baseline, and up to 18 months (European participants), or 5 Years (United States participants)
Evaluation of patient reported outcome measure: Kansas City Cardiomyopathy Questionnaire 23 (KCCQ-23)
The KCCQ-23 is a disease-specific health status instrument composed of 23 items that quantifies the domains of physical limitations, symptoms, self-efficacy, social limitation and quality of life from heart failure. Scores range from 0-100, in which higher scores reflect better health status. United States participants only
Time frame: Baseline, and up to 5 Years
Evaluation of patient reported outcome measure: EuroQol Five Dimensions Questionnaire (5-level) (EQ-5D-5L): Health Utility Index
The EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L health utility index and EQ Visual Analog Scale (VAS). EQ-5D-5L health utility index is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participants select an answer for each of the 5 dimensions that best matches his/her health "today". Responses are used to generate a weighted summary index, which ranges from 0 to 1.00. A higher score indicates better health and positive changes from baseline indicate improvement of health. United States participants only
Time frame: Baseline, and up to 5 Years
Evaluation of patient reported outcome measure: EQ-5D-5L: VAS
The EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and VAS. The VAS self-rating records the participant's own assessment of his or her overall health status at the time of completion, on a vertical line VAS with scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). A higher score indicates better health and positive changes from baseline indicate improvement of health status. United States participants only
Time frame: Baseline, and up to 5 Years
Evaluation of biomarkers of response: NT-proBNP
Change From Baseline in Serum concentration of NT-proBNP. United States participants only
Time frame: Baseline, and up to 5 Years
Evaluation of biomarkers of response: Cardiac troponin
Change From Baseline in Serum Concentration of Cardiac Troponins. United States participants only
Time frame: Baseline, and up to 5 Years
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Showing the first 100 of 101 sites across 9 countries. Choose a country and city above to see the rest.
Plan to share: No
Started Aug 2022 (actual). Primary completion is estimated for Aug 2029, 84 months after the start.
Of 82 observational studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 85 months of starting (the median), counting those still running; a quarter within 43. This study's planned 84 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cardiomyopathy, Hypertrophic →